MIRA Pharmaceuticals Inc. (NASDAQ: MIRA) announced positive results from its completed Phase 1 clinical trial evaluating Ketamir-2, an oral NMDA ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE